Overview

Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA

Status:
Completed
Trial end date:
2021-01-29
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate the efficacy and safety of intravenous ferric carboxymaltose (FCM), compared to oral iron, in pediatric participants who have iron deficiency anemia.
Phase:
Phase 3
Details
Lead Sponsor:
American Regent, Inc.
Luitpold Pharmaceuticals
Treatments:
Ferric Compounds
Iron